InMode Reports Q2 2025 Financial Highlights: Revenue Reaches $95.6M

YOKNEAM, Israel, July 30, 2025 — InMode Ltd. (Nasdaq: INMD), a prominent global provider of innovative medical technologies, announced its financial results for the second quarter of 2025, reflecting significant revenue growth amid challenging market conditions. The company reported consolidated revenues of $95.6 million for the quarter ending June 30, 2025, marking a notable increase from $86.4 million in the same period of 2024.

InMode's gross margins remained strong at 80%, consistent with the previous year's second quarter, despite facing macroeconomic uncertainties that have influenced consumer behavior and business operations. Moshe Mizrahy, InMode's Chief Executive Officer, commented, "The second quarter reflects the broader trends we've seen in recent months, with persistent external headwinds, including ongoing macroeconomic uncertainty and a more cautious consumer behavior. While these factors have impacted our results, we remain disciplined in our execution and committed to investing in our growth drivers."

The company's operating income for the second quarter was $22.9 million, with a non-GAAP operating income of $26.3 million. The net income for the quarter was reported at $26.7 million, or $0.42 per diluted share, compared to $23.8 million, or $0.28 per diluted share, in the same quarter of the previous year. Non-GAAP net income was $30.1 million, or $0.47 per diluted share.

InMode highlighted a decrease in revenues from consumables and services, which totaled $19.8 million, a 6% decline compared to the previous year. Despite this, the company’s international sales, particularly from Europe, reached record highs, partially offsetting domestic challenges. Yair Malca, Chief Financial Officer, noted, "Our strong balance sheet is a key asset in these uncertain times, giving us the flexibility to retain top talent, expand globally, and continue leading the industry with cutting-edge technologies."

Looking ahead, InMode has adjusted its full-year revenue guidance for 2025, anticipating revenues between $365 million to $375 million, down from previous estimates of $395 million to $405 million. Management expects non-GAAP gross margins to remain between 78% and 80%, reflecting ongoing adjustments to market conditions and operational strategies.

The current geopolitical climate in Israel, marked by renewed tensions following a ceasefire collapse in March, remains a concern for the company. InMode reported that, to date, its operations have not been materially affected, but they continue to monitor the situation closely. Mizrahy stated, "We are committed to navigating these challenges effectively while focusing on our long-term goals."

InMode's financial results underscore its resilience in a fluctuating market, with strategic investments aimed at sustaining growth and innovation in the medical technology sector. The company's upcoming conference call is scheduled for July 30, 2025, at 8:30 a.m. Eastern Time, where management will further discuss these developments and answer investor questions.